Novo Nordisk right now introduced the presentation of 34 abstracts highlighting the breadth of its portfolio on the upcoming 84th Worldwide Convention on Biotechnology.th American Diabetes Affiliation (ADA) Scientific Periods. The convention can be held in individual and nearly in Orlando, USA, from June 21 to 24, 2024.
Particular scientific periods may also current extra information from three landmark trials of semaglutide. The trials are investigating different potential advantages of semaglutide, together with evaluating renal and cardiovascular endpoints in individuals with sort 2 diabetes and continual kidney illness (FLOW, semaglutide 1.0 mg) and cardiovascular and glucose-related endpoints in individuals with weight problems and heart problems, with and with out diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg).
We all know that cardiometabolic illnesses corresponding to heart problems, continual kidney illness, weight problems and sort 2 diabetes are sometimes interrelated and might happen in the identical affected person. We’d like to develop medicines that tackle a number of aspects of those illnesses. The intensive information being introduced on the ADA this yr replicate this aim. Particularly, the FLOW and SELECT information discover methods to deal with frequent comorbidities of diabetes and weight problems, corresponding to kidney illness and heart problems.”
Stephen Gough, Senior Vice President and World Chief Medical Officer, Novo Nordisk
All abstracts can be printed on the journal web site ®Knowledge from the scientific periods can be made accessible after their presentation.
Abstract of the lectures
Scientific periods
| The First Devoted Renal Outcomes Research of GLP1-RA As soon as-Weekly Semaglutide – Outcomes from the FLOW Research (Scientific Session; June 24, 1:30–3:00 p.m. EST) |
| SELECT Research – Original insights into glycemia, irritation and coronary heart failure (scientific session; June 22, 08:00–09:00 EST) |
| The STEP-HFpEF and STEP-HFpEF-DM trials – Focusing on weight problems to deal with coronary heart failure (scientific session; June 23, 4:30 p.m.–6:00 p.m. EST) |
Poster and oral shows
| diabetes |
|
- Comparative efficacy of semaglutide in sort 2 diabetes – outcomes of a randomized pragmatic scientific trial (230-OR) within the second yr
|
- Lengthy-term efficacy related to upkeep doses of once-weekly semaglutide in US adults with poorly managed sort 2D (766-P)
|
- Semaglutide in sufferers with peripheral arterial illness and sort 2 diabetes: comorbidities and concomitant medicines from the STRIDE research (784-P)
|
- Actual-world results of once-weekly injectable semaglutide on weight, BMI and HbA1C Outcomes in sort 2 diabetes: an observational research (PAUSE) (857-P)
|
- Results of once-weekly injectable semaglutide (Sema OW) in contrast with sodium-glucose cotransporter-2 inhibitors (SGLT2i) on HbA1c, weight and healthcare useful resource utilization (HCRU) in real-world sort 2 diabetes (T2D) – an observational research (PAUSE) (1884-LB)
|
|
- Consider the effectiveness of Oral semaglutide in Chinese language sufferers with sort 2 diabetes based on baseline traits: post-hoc evaluation of PIONEER 11 and 12 (752-P)
|
- Results of real-world fasting on adherence to dosing directions and efficacy of oral semaglutide throughout Ramadan in individuals with sort 2 diabetes: O-SEMA-Lickety-split subanalysis (808-P)
|
|
- CagriSema improves insulin sensitivity in diet-obese rats (763-P)
|
|
- Utilization and prices of well being sources with well timed vs. delayed initiation of basal insulin remedy (816-P)
|
- Demographic, scientific and therapy traits of sufferers with well timed vs. delayed basal insulin initiation (817-P)
|
- No proof of elevated activity-induced hypoglycemia with once-weekly insulin icodec in contrast with once-daily basal insulin in sort 1 diabetes: ONWARDS 6 (824-P)
|
- Efficacy and security of once-weekly insulin icodec in contrast with once-daily basal insulin in individuals with sort 2 diabetes based on renal operate: ONWARDS 1–5 (826-P)
|
- No proof of elevated activity-induced hypoglycemia with once-weekly insulin icodec in contrast with once-daily basal insulin in sort 2 diabetes: ONWARDS 1-5 (830-P)
|
- Adherence to app-based dosing directions for once-weekly insulin icodec in insulin-naive sort 2D: post-hoc evaluation of ONWARDS 5 (836-P)
|
- Affect of age on the efficacy and security of once-weekly insulin icodec in contrast with once-daily insulin in sort 2 diabetes (ONWARDS 1–5) (838-P)
|
- Efficacy and security of once-weekly insulin icodec in contrast with once-daily basal insulin in sort 2 diabetes based on the exhaust of a glucagon-like peptide-1 receptor agonist at baseline: ONWARDS 1–5 (840-P)
|
- Efficacy and security of once-weekly insulin icodec in contrast with once-daily basal insulin in sort 2 diabetes by race and ethnicity: ONWARDS 1–5 (841-P)
|
- Price-effectiveness of insulin icodec for the therapy of sort 2 diabetes in Canada (1046-P)
|
- Efficacy and security outcomes with once-weekly insulin icodec in contrast with once-daily insulin degludec in sort 1 diabetes based on glycemic variability: ONWARDS 6 post-hoc evaluation (1882-LB)
|
|
- Affect of the functionally selective insulin analogue NNC-965 on cardiac construction and performance in comparison with insulin glargine (IGla) (822-P)
|
- Improved glycemic management in individuals with sort 2 diabetes (T2D) beginning or switching to insulin degludec/insulin aspart (IDegAsp) in a real-world setting in China (publication solely)
|
|
- Persistence and adherence to once-weekly GLP-1 receptor agonists in sufferers with sort 2 diabetes and atherosclerotic heart problems in a real-world setting (740-P)
|
- Results of newer GLP-1 RAs on HbA1c in adults with sort 2 diabetes in the US: a population-level time sequence evaluation (774-P)
|
- Understanding attitudes towards basal insulin: insights from a world survey of individuals with sort 2 diabetes (833-P)
|
|
|
- Prevalence of atherosclerotic heart problems in adults with sort 2 diabetes in Jordan: the PACT-MEA research (1789-LB)
|
- In vivo chain cleavage of human insulin (2032-LB)
|
| Digital Well being |
- Enchancment in time in goal vary after introduction of an clever insulin pen in Austria (842-P)
|
- Multinational evaluation of components related to missed bolus insulin injections utilizing sensible pen information (843-P)
|
| weight problems |
|
- CONCRETE – Characterization of sufferers who Telemedicine and branded weight problems medicine for medical weight management: a retrospective evaluation (1684-P)
|
- Scientific outcomes in sufferers with weight problems or obese handled with semaglutide 2.4 mg: a real-world retrospective cohort research in the US (SCOPE 2) (1691-P)
|
- Modelling the consequences of semaglutide 2.4 mg in US sufferers with atherosclerotic heart problems and a BMI ≥27 kg/m2 (1981-LB)
|
|
- Affected person-centered scientific choice assist in weight administration: a proof-of-concept research (1101-P)
|
- Prevalence, traits, and scientific burden in sufferers with obese or weight problems and established ASCVD in a US real-world setting (1692-P)
|
About Ozempic®
Semaglutide administered subcutaneously as soon as weekly is permitted in doses of 0.5 mg, 1.0 mg and a couple of.0 mg underneath the model identify Ozempic.® and is indicated as an adjunct to weight loss plan and train to enhance glycemic management in adults with sort 2 diabetes and to scale back the chance of main adversarial cardiovascular occasions (cardiovascular demise, non-fatal myocardial infarction, or non-fatal stroke) in adults with sort 2 diabetes and present heart problems.
About Rybelsus®
Oral semaglutide is run as soon as day by day and is permitted in three therapeutic doses, 3 mg, 7 mg and 14 mg, underneath the model identify Rybelsus.®It’s indicated for the therapy of adults with inadequately managed sort 2 diabetes mellitus to enhance glycemic management as an adjunct to weight loss plan and train.
About Wegovy®
Semaglutide 2.4 mg administered subcutaneously as soon as weekly is permitted underneath the model identify Wegovy.® and is indicated together with a calorie-restricted weight loss plan and elevated bodily exercise to scale back the chance of main cardiovascular occasions (cardiovascular demise, non-fatal myocardial infarction, or non-fatal stroke) in adults with documented heart problems and both weight problems or obese, as nicely as to scale back extra physique weight and preserve weight reduction in the long run in adults and pediatric sufferers aged 12 years and older with weight problems and in adults with obese and a minimum of one weight-related comorbidity.
